Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51,722,000 | $46,660,000 | $43,461,000 | $43,974,000 |
| % Growth | 10.8% | 7.4% | -1.2% | – |
| Cost of Goods Sold | $12,827,000 | $12,472,000 | $11,582,000 | $11,735,000 |
| Gross Profit | $38,895,000 | $34,188,000 | $31,879,000 | $32,239,000 |
| % Margin | 75.2% | 73.3% | 73.4% | 73.3% |
| R&D Expenses | $10,022,000 | $11,371,000 | $9,172,000 | $8,641,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12,566,000 | $12,517,000 | $12,193,000 | $12,827,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,763,000 | $531,000 | $2,568,000 | $715,000 |
| Operating Expenses | $24,351,000 | $24,419,000 | $23,933,000 | $22,183,000 |
| Operating Income | $14,544,000 | $9,769,000 | $7,946,000 | $10,056,000 |
| % Margin | 28.1% | 20.9% | 18.3% | 22.9% |
| Other Income/Exp. Net | -$904,000 | -$646,000 | -$769,000 | $14,474,000 |
| Pre-Tax Income | $13,640,000 | $9,123,000 | $7,177,000 | $24,530,000 |
| Tax Expense | $1,701,000 | $551,000 | $1,128,000 | $1,625,000 |
| Net Income | $11,941,000 | $14,850,000 | $6,955,000 | $24,021,000 |
| % Margin | 23.1% | 31.8% | 16% | 54.6% |
| EPS | 5.92 | 7.15 | 3.19 | 10.71 |
| % Growth | -17.2% | 124.1% | -70.2% | – |
| EPS Diluted | 5.87 | 7.1 | 3.17 | 10.63 |
| Weighted Avg Shares Out | 2,018,282 | 2,076,794 | 2,181,180 | 2,242,601 |
| Weighted Avg Shares Out Dil | 2,035,000 | 2,092,000 | 2,197,000 | 2,260,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $567,679 | $629,244 | $377,735 | $71,000 |
| Interest Expense | $1,036,413 | $876,124 | $834,624 | $905,000 |
| Depreciation & Amortization | $6,069,000 | $8,277,000 | $6,705,000 | $5,597,000 |
| EBITDA | $20,715,000 | $18,255,000 | $14,682,000 | $30,914,000 |
| % Margin | 40.1% | 39.1% | 33.8% | 70.3% |